This project gives an answer to the scope of the “Societal Challenges” pillar of Horizon 2020, under the “Health, demographic change and wellbeing” work programme and specifically under the “Better Health and Care, Economic Growth and Sustainable Health Systems” topic: SC1-BHC-15-2018: New anti-infective agents for prevention and/or treatment of Neglected Tropical Disease (NTD).
The TT4CL consortium consists of 7 partner institutions from 4 European countries (UK, Belgium, the Netherlands and Germany) and one country to which cutaneous leishmaniasis is endemic, The Islamic Republic of Iran.
TT4CL (Targeted treatment for cutaneous leishmaniasis) is a new Horizon 2020-funded project which aims to reduce the burden of a Neglected Tropical Diseases (NTD) and its social and economic impacts. Horizon 2020, the European Union’s (EU) research and innovation programme, helps to bridge the gap between preclinical and clinical development and thus helps to advance promising new drug candidates along the development pipeline. The TT4CL consortium, which brings together partners from academia and industry in Europe and disease-endemic countries, has been awarded EUR3.75 million to develop an oral treatment, D121, against one of the most neglected tropical diseases, cutaneous leishmaniasis.
